Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy

Among patients with intermediate-/high-risk myelofibrosis who had progression or suboptimal response on stable ruxolitinib dose, the addition of navitoclax to ruxolitinib resulted ≥ 35% spleen volume reduction by week 24 in 26.5% of patients; 50% reduction in total symptom score by week 24 in 30% of patients; and improvement in bone marrow fibrosis by 1-2 grades among 33% of evaluable patients.